Gozellix® Revolutionizes Prostate Cancer Imaging with FDA Approval

In a major win for prostate cancer patients, Telix Pharmaceuticals has secured FDA approval for Gozellix®, a next-generation PSMA-PET imaging agent designed to enhance accuracy and accessibility. By extending the shelf life to six hours, Gozellix® ensures broader availability, especially in areas where PSMA imaging was previously limited. The innovative formulation allows for scalable production, giving imaging centers the flexibility to increase efficiency and patient throughput. With millions of men living with prostate cancer in the U.S., this approval is set to redefine diagnostic standards and improve early detection.

Gozellix® joins Illuccix®, Telix’s existing PSMA-PET imaging agent, offering physicians more choices for patient care. The approval comes with a reimbursement pathway that is expected to minimize out-of-pocket costs, making this state-of-the-art imaging technology accessible to a larger patient population. Kevin Richardson, CEO of Telix Precision Medicine, emphasized the company’s commitment to innovation, stating, "With Gozellix®, we are bringing next-level PSMA-PET imaging to more patients, ensuring they receive the precise care they deserve."